Claims for Patent: 10,420,734

Summary for Patent: 10,420,734

Title:	Method of treating cancer using selective estrogen receptor modulators
Abstract:	Disclosed herein are methods of treating subjects suffering from estrogen receptor positive cancer of the brain by administering a selective estrogen receptor degrader (SERM). Also disclosed are methods of treating a cancer that is resistant to an estrogen receptor modulator by administering a SERM.
Inventor(s):	Wardell Suzanne E., Nelson Erik R., McDonnell Donald P.
Assignee:	Duke University
Application Number:	US15129197
Patent Claims:	2. The method of claim 1 , wherein the estrogen receptor positive breast cancer is de novo resistant to the estrogen receptor modulator.3. The method of claim 1 , wherein the resistance to the estrogen receptor modulator is acquired.4. The method of claim 1 , wherein the estrogen receptor modulator is a selective estrogen receptor modulator (SERM).5. The method of claim 4 , wherein the SERM is tamoxifen claim 4 , idoxifene claim 4 , raloxifene or ICI 182 claim 4 ,780.6. The method of claim 1 , wherein the estrogen receptor modulator is an aromatase inhibitor.7. The method of claim 6 , wherein the aromatase inhibitor is anastrozole claim 6 , letrozole or exemestane.8. The method of claim 1 , wherein an effective amount of the compound is administered.9. The method of claim 8 , wherein the effective amount is from about 200 mg/day to about 500 mg/day.10. The method of claim 9 , wherein the effective amount is about 400 mg/day.11. The method of claim 10 , wherein the compound is administered by oral administration claim 10 , intravenous administration claim 10 , intradermal injection claim 10 , intramuscular injection or subcutaneous injection.12. The method of claim 11 , wherein the compound is administered by oral administration.13. The method of claim 12 , wherein the estrogen receptor modulator is tamoxifen claim 12 , idoxifene claim 12 , raloxifene claim 12 , ICI 182 claim 12 ,780 claim 12 , or an aromatase inhibitor.14. The method of claim 13 , further comprising administering an effective amount of at least one compound selected from the group consisting of a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6 inhibitor) claim 13 , an antiestrogen claim 13 , a ligand of retinoic acid or retinoxic X receptor claim 13 , an antiprogestin claim 13 , an antiandrogen claim 13 , vitamin D or metabolite thereof claim 13 , a farnesyl transferase inhibitor claim 13 , a PPARα or gamma agonist and a MAP kinase inhibitor.15. The method of claim 14 , wherein the at least one compound is a CDK4/6 inhibitor.16. The method of claim 10 , wherein the composition is administered daily as a single dose.18. The method of claim 17 , wherein the estrogen receptor positive breast cancer is de novo resistant to the estrogen receptor modulator.19. The method of claim 17 , wherein the resistance to the estrogen receptor modulator is acquired.20. The method of claim 17 , wherein the estrogen receptor modulator is a selective estrogen receptor modulator (SERM).21. The method of claim 20 , wherein the SERM is tamoxifen claim 20 , idoxifene claim 20 , raloxifene or ICI 182 claim 20 ,780.22. The method of claim 17 , wherein the estrogen receptor modulator is an aromatase inhibitor.23. The method of claim 22 , wherein the aromatase inhibitor is anastrozole claim 22 , letrozole or exemestane.24. The method of claim 17 , wherein the effective amount is about 400 mg/day.25. The method of claim 24 , wherein the estrogen receptor modulator is tamoxifen claim 24 , idoxifene claim 24 , raloxifene claim 24 , ICI 182 claim 24 ,780 claim 24 , or an aromatase inhibitor.26. The method of claim 25 , further comprising administering an effective amount of at least one compound selected from the group consisting of a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6 inhibitor) claim 25 , an antiestrogen claim 25 , a ligand of retinoic acid or retinoxic X receptor claim 25 , an antiprogestin claim 25 , an antiandrogen claim 25 , vitamin D or metabolite thereof claim 25 , a farnesyl transferase inhibitor claim 25 , a PPARα or gamma agonist and a MAP kinase inhibitor.27. The method of claim 26 , wherein the at least one compound is a CDK4/6 inhibitor.28. The method of claim 24 , wherein the composition is administered daily as a single dose.29. The method of claim 24 , wherein the composition is administered daily as a multi-dose.